Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|September 25, 2023

Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone

Author(s)Jill Murphy

The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.

The drug development partnership between Evecxia Therapeutics and Quotient Sciences has seen the success of a Phase I clinical testing program for Evecxia’s drug candidate EVX-101, which is in development to treat major depressive disorder (MDD).

According to the release, Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders such as MDD. The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.

EVX-101 is a novel, proprietary, sustained-release tablet formulation of 5-hydroxtryptophan, or 5-HTP, the natural precursor to serotonin, and low-dose carbidopa. Further, 5-HTP is the active compound and carbidopa functions as an absorption enhancer for 5-HTP.

The new EVX-101 drug candidate into a Phase II adjunctive treatment study in patients with MDD who are responding inadequately to a first-line SSRI/SNRI antidepressant.

“Quotient Sciences’ expertise in developing and optimizing modified-release formulations coupled with their ability to integrate rapid clinical assessments allowed us to produce a new drug candidate, EVX-101, in a highly condensed time frame,” said Jacob Jacobsen, PhD, CEO of Evecxia, in a press release. “We are very pleased with the outcome of this partnership and appreciate the collaboration between both organizations to aid in the advancement of EVX-101 towards helping patients who are suffering from the life-limiting effects of MDD.”

Mark Egerton, PhD, CEO of Quotient Sciences, added how the partnership with Evecxia has greatly accelerated the development timeline of their EVX-101 program. “Improving mental health is a global goal and the industry must work hard to get treatments to patients more quickly,” he said in a press release. “We are proud that this collaboration and our expertise has enabled Evecxia to successfully progress EVX-101 onward into Phase II studies to provide patients who are suffering from MDD with new treatment options.”

Source: Quotient Sciences


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.